Table 6

Correlations of clinical features with systemic sclerosis-associated autoantibodies

Quantitative traits

Clinical data

Age at disease onset

n

Mean ± SD (years)

P*

Total

781

47.7 (14.2)

Anti-centromere

273

51.3 (12.5)

< 0.0001

Anti-topoisomerase I

238

46.0 (14.0)

0.0076

Anti-fibrillarin

12

38.8 (16.0)

0.0404

Anti-U1-RNP

39

38.2 (15.0)

< 0.0001

Anti-La

15

37.9 (18.1)

0.0431

Autoantibody-negative

36

52.9 (14.7)

0.0205

Rodnan skin score

n

Mean score ± SD

P

Total

750

10.2 (9.4)

Anti-centromere

275

6.4 (6.0)

< 0.0001

Anti-topoisomerase I

227

14.1 (9.7)

< 0.0001

Anti-RNA polymerase

27

15.7 (11.7)

0.0091

Anti-fibrillarin

10

21.2 (15.0)

0.0108

Anti-U1-RNP

35

6.9 (9.2)

0.0053

Erythrocyte sedimentation rate

n

Mean ± SD (mm/hour)

P

Total

741

19.46 (16.7)

Anti-topoisomerase I

227

22.95 (19.1)

0.0002

Anti-PM-Scl

36

12.19 (9.4)

0.0014

Anti-Ro52

167

22.05 (18.8)

0.0374

Anti-Ro60

53

28.47 (19.6)

< 0.0001

Anti-La

16

28.56 (20.1)

0.0447

PM-Scl = polymyositis and scleroderma; RNP = ribonucleoprotein; SSc, systemic sclerosis. *P-value calculated by Mann-Whitney rank-sum test for comparison of antibody-positive vs antibody-negative patients.

Mierau et al. Arthritis Research & Therapy 2011 13:R172   doi:10.1186/ar3495